CD20 inhibitors(B-lymphocyte antigen CD20 inhibitors), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects), CD20-directed cytolytic effects

+ [1]

Therapeutic Areas

Immune System DiseasesSkin and Musculoskeletal DiseasesNeoplasms+ [1]

Active Indication-

Inactive Indication

CD20 Positive B-Cell Non-Hodgkin LymphomaDiffuse Large B-Cell LymphomaRheumatoid Arthritis

Originator Organization

Teva Pharmaceutical Industries Ltd.

Active Organization-

Inactive Organization

Teva Branded Pharmaceutical Products R&D, Inc.

Teva Pharmaceutical Industries Ltd.

Lonza Group AG

Drug Highest PhaseDiscontinuedPhase 3

First Approval Date-

Regulation-

Gene Sequence

Sequence Code 83181H

The sequence is quoted from: *****

Sequence Code 27145L

The sequence is quoted from: *****

Clinical Trials associated with Rituximab biosimilar(Teva Pharmaceutical Industries Ltd.)

NCT01205737 / CompletedPhase 1

A Phase Ib, Double Blind RCT to Evaluate and Compare the PK, PD and Safety of MabThera® With TL011, in Combination With CHOP, in Subjects With CD20+ DLBCL

This is a prospective international, multi-center, randomized, double-blind controlled study designed to assess and compare the pharmacokinetics, pharmacodynamics and the safety of MabThera® and TL011, in combination with CHOP in previously untreated patients with diffuse large B cell lymphoma.

Start Date01 Sep 2010

Sponsor / Collaborator

Teva Branded Pharmaceutical Products R&D, Inc.

NCT01123070 / CompletedPhase 1

A Phase Ib Study Evaluating Safety, Pharmacokinetic and Pharmacodynamic Profiles of a Single Course of TL011 Infusions in Subjects With Severe, Active Rheumatoid Arthritis

The purpose of this study is to determine the safety and pharmacology of TL011 in patients with severe rheumatoid arthritis.

Start Date05 Feb 2010

Sponsor / Collaborator

Teva Pharmaceutical Industries Ltd.

100 Clinical Results associated with Rituximab biosimilar(Teva Pharmaceutical Industries Ltd.)

100 Translational Medicine associated with Rituximab biosimilar(Teva Pharmaceutical Industries Ltd.)

100 Patents (Medical) associated with Rituximab biosimilar(Teva Pharmaceutical Industries Ltd.)

Literatures (Medical) associated with Rituximab biosimilar(Teva Pharmaceutical Industries Ltd.)

01 Oct 2023·Current Drug Delivery

Pharmaceutical Considerations of Translabial Formulations for Treatment of Parkinson’s Disease: A Concept of Drug Delivery for Unconscious Patients

Article

Author: Tiwari, Gaurav ; Tiwari, Ruchi ; Kaur, Arshpreet

Purpose:The goal of the present research was to isolate a biopolymer from Phaseolus vulgaris (P. vulgaris) and Zea mays (Z. mays) plants and used it to construct Resveratrol (RES)-loaded translabial films.Methods:Biopolymers were extracted from P. vulgaris and Z. mays seeds using a simple process. Separated biopolymers, sodium carboxymethylcellulose (SCMC) and tragacanth were subjected to formulation development by incorporating RES-loaded translabial films. The Fourier-transform infrared spectroscopy (FTIR), physical appearance, weight, thickness, folding endurance, swelling index, surface pH, percent moisture absorption, percent moisture loss, vapor transfer rate, and content uniformity of the translabial films were examined. The mucoadhesive, ex-vivo permeation, in vivo and stability studies, were performed.Results:The results showed that RES-loaded translabial films produced from P. vulgaris and Z. mays biopolymers exhibited exceptional mucoadhesive, stability, and permeation properties. Results revealed that the best formulations were prepared from a combination of biopolymer (P. vulgaris C or Z. mays C) with tragacanth. Formulations with tragacanth revealed good swelling and thus permeation profiles. In vivo release of TL 11 was found to be 24.05 ng/ml in 10 hours and it was stable enough at 45oC.Conclusion:This research suggested that RES-loaded translabial formulations can be potentially used for the treatment of Parkinson’s disease with good patient compliance to geriatric and unconscious patients.

100 Deals associated with Rituximab biosimilar(Teva Pharmaceutical Industries Ltd.)

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	L01XC02	-

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
CD20 Positive B-Cell Non-Hodgkin Lymphoma	Phase 3	FR	Teva Branded Pharmaceutical Products R&D, Inc.	01 Sep 2010
CD20 Positive B-Cell Non-Hodgkin Lymphoma	Phase 3	PL	Teva Branded Pharmaceutical Products R&D, Inc.	01 Sep 2010
CD20 Positive B-Cell Non-Hodgkin Lymphoma	Phase 3	EE	Teva Branded Pharmaceutical Products R&D, Inc.	01 Sep 2010
CD20 Positive B-Cell Non-Hodgkin Lymphoma	Phase 3	BG	Teva Branded Pharmaceutical Products R&D, Inc.	01 Sep 2010
Diffuse Large B-Cell Lymphoma	Phase 3	-	Lonza Group AG	-
Diffuse Large B-Cell Lymphoma	Phase 3	-	Lonza Group AG	-
Rheumatoid Arthritis	Phase 3	-	Lonza Group AG	-
Rheumatoid Arthritis	Phase 3	-	Teva Pharmaceutical Industries Ltd.	-
Rheumatoid Arthritis	Phase 3	-	Teva Pharmaceutical Industries Ltd.	-
Rheumatoid Arthritis	Phase 3	-	Lonza Group AG	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01123070 (CTgov)	Phase 1	Rheumatoid Arthritis	54	TL011 (Double Blind TL011 1000 mg)	vwehlhhsdt(ngmchhpssx) = sceklxnudl nlduhwlkfx (hzqrkkosmc, zlkzzcqbri - lrqzxezcgl) View more	-	04 Oct 2021
				MabThera (Double Blind MabThera 1000 mg)	vwehlhhsdt(ngmchhpssx) = vmjytjnpos nlduhwlkfx (hzqrkkosmc, wihmupuayf - yegrfszmix) View more
ASCO2021	Not Applicable	Chronic Lymphocytic Leukemia First line	201	Rituximab	jvubullpik(neloityqwh) = npjfxhmmkd mmuvwexpkh (dfvcgjbesy ) View more	-	28 May 2021
				Rituximab-abbs	jvubullpik(neloityqwh) = zlalfkiwpa mmuvwexpkh (dfvcgjbesy ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis